Ke Ning Bio

Pleryon Therapeutics is a pharmaceutical company focused on developing ophthalmic and orthopedic therapeutics through biomaterial innovations. Originating as a spin-off from the Laboratory of Drug Delivery and Biomaterials at the Hong Kong University of Science and Technology (HKUST), the company was co-founded by Professor Ying Chau, Director of HKUST's Bioengineering Program, and Dr. Yu Yu, a biomaterial inventor and entrepreneur. The core team possesses over two decades of research and development experience in biomaterials and drug delivery, with backgrounds in renowned universities and multinational pharmaceutical companies.

The company's business model centers on leveraging its proprietary biomaterial design technology to address significant unmet medical needs. It operates with a multi-platform strategy to regulate pharmaceutical products, establishing research centers in both Shenzhen and Shanghai. The business makes money by developing and bringing to market a pipeline of pharmaceutical products. A significant milestone was achieved in April 2022, when the company secured close to 100 million RMB in a Pre-A funding round led by Lapam Investment, with participation from Kaitai Capital and existing shareholder Zero2IPO Venture. This capital is intended to support the preclinical development of its pipelines, particularly in ophthalmology and orthopedics. In 2021, Pleryon established a residency in JLABS@Shanghai, a life science incubator under Johnson & Johnson Innovation.

Pleryon's product pipeline is diverse, utilizing its technology to enable previously undruggable compounds to be developed as therapeutics. Key products in development include a contact lens lubricant, veterinary therapeutics for dry eye, and a long-acting anti-VEGF therapeutic for age-related macular degeneration. The company's programs are primarily focused on osteoarthritis, ophthalmology, and regenerative aesthetics. By employing advanced polymer and drug delivery systems, Pleryon aims to create a scalable product pipeline with substantial market potential.

Keywords: ophthalmic therapeutics, biomaterial innovations, drug delivery systems, polymer therapeutics, orthopedics, age-related macular degeneration, dry-eye treatment, contact lens lubricant, regenerative aesthetics, preclinical development, pharmaceutical R&D, venture capital, life science incubator, HKUST spin-off, anti-VEGF, osteoarthritis treatment, advanced polymers, JLABS, Lapam Investment, Kaitai Capital